Pancreas

M402

Description:

M402 is a heparin sulfate mimetic designed to have antitumor effect without the anticoagulant activity. In this Phase I/II study M402 is administered as daily subcutaneous injection with Gemcitabine in patients with metastatic pancreatic cancer who have not received prior chemotherapy.


Type(s) of Cancer: Pancreas
Study Phase(s): Phase I
Phase II
Contact: Epp Goodwin at (210) 450-5798

MLN0264

Description:

MLN0264 is an antibody-drug conjugate targeting guanylyl cyclase C (GCC), often overexpressed on the surface of gastrointestinal cancers. MMAE (monomethyl auristatin) is the cytotoxic agent in this conjugate that inhibits microtubules. In this Phase II study MLN0264 is administered intravenously every 3 weeks in previously treated patients with advanced or metastatic pancreas adenocarcinoma that express GCC.


Type(s) of Cancer: Pancreas
Study Phase(s): Phase II
Contact: Epp Goodwin at (210) 450-5798